natgillin/translations-raw huggingface dataset:
The anti-toxin intestinal antibodies prevent the cholera toxin from binding to the intestinal mucosal surface thereby preventing the toxin-mediated diarrhoeal symptoms.
Antitoksinska protutijela u crijevima sprječavaju vezanje toksina kolere na površinu sluznice crijeva i tako sprječavaju proljev prouzročen toksinom.
The anti-tumour activity of blinatumomab immunotherapy is not dependent on T-cells bearing a specific TCR or on peptide antigens presented by cancer cells, but is polyclonal in nature and independent of human leukocyte antigen (HLA) molecules on target cells.
Antitumorska aktivnost imunoterapije blinatumomabom ne ovisi o prisutnosti specifičnog TCR-a na površini T limfocita ili o specifičnim peptidima antigenima na površini tumorskih stanica, već je po prirodi poliklonska i ne ovisi o ljudskim leukocitnim antigenima (HLA) na ciljanim stanicama.
The anti-tumour activity of topotecan involves the inhibition of topoisomerase-I, an enzyme intimately involved in DNA replication as it relieves the torsional strain introduced ahead of the moving replication fork.
Antitumorska aktivnost topotekana obuhvaća inhibiciju topoizomeraze-I, enzima neposredno uključenog u replikaciju DNK koji opušta torzijsku napetost, što dovodi do razdvajanja DNK uzvojnice.
The anti-tumour activity of topotecan involves the inhibition of topoisomerase-I, an enzyme intimately involved in DNA replication as it relieves the torsional strain introduced ahead of the moving replication fork.
Antitumorska aktivnost topotekana uključuje inhibiciju topoizomeraze-I, enzima neposredno uključenog u replikaciju DNK koji opušta torzijsku napetost, ispred napredujućih replikacijskih rašlji.
The antibacterial intestinal antibodies prevent the bacteria from attaching to the intestinal wall thereby impeding colonisation of V. cholerae O1.
Antibakterijska protutijela u crijevima sprječavaju bakterije da se pričvrste na stijenku crijeva i tako ometaju kolonizaciju V. cholerae O1.
the antibiotic ciprofloxacin used against infections
antibiotika ciprofloksacina koji se upotrebljava protiv infekcija
The antibiotic linezolid is a reversible non-selective MAOI and should not be given to patients treated with ARICLAIM (see section 4.4).
Antibiotik linezolid je reverzibilan neselektivan MAO inhibitor i ne smije se davati bolesnicima koji se liječe lijekom ARICLAIM (vidjeti dio 4.4).
The antibiotic linezolid is a reversible non-selective MAOI and should not be given to patients treated with Cymbalta (see section 4.4).
Antibiotik linezolid je reverzibilan neselektivan MAO inhibitor i ne smije se davati bolesnicima koji se liječe lijekom Cymbalta (vidjeti dio 4.4).
The antibiotic linezolid is a reversible non-selective MAOI and should not be given to patients treated with Duloxetine Lilly (see section 4.4).
Antibiotik linezolid je reverzibilan neselektivan MAO inhibitor i ne smije se davati bolesnicima koji se liječe lijekom Duloksetin Lilly (vidjeti dio 4.4).
The antibiotic linezolid is a reversible non-selective MAOI and should not be given to patients treated with YENTREVE (see section 4.4).
Antibiotik linezolid je reverzibilan neselektivan MAO inhibitor i ne smije se davati bolesnicima koji se liječe lijekom YENTREVE (vidjeti dio 4.4).
The antibodies elicited by Nimenrix were similar or higher than those induced by licensed meningococcal vaccines (i.e., MenC-CRM vaccine in subjects aged 12-23 months and ACWY-PS vaccine in subjects older than 2 years of age).
Protutijela nastala kao odgovor na Nimenrix bila su slična ili veća od one potaknute odobrenim meningokoknim cjepivima (tj. cjepivom MenC-CRM u ispitanika u dobi od 12 do 23 mjeseci i cjepivom ACWY-PS u ispitanika starijih od 2 godine starosti).
The antibodies form a part of the immune system that will protect your child against these diseases.
Protutijela čine dio imunološkog sustava koji štiti Vaše dijete od ovih bolesti.
The antibodies had no impact on clinical pharmacodynamics, efficacy or safety.
Ta protutijela nisu utjecala na kliničku farmakodinamiku, djelotvornost ili sigurnost.
The antibody response in A/Vietnam/1203/2004 P/LAIV-primed subjects also exceeded that observed after 2 doses of inactivated vaccine in P/LAIV-naïve subjects (see Table 3).
Odgovor antitijela u ispitanika primarno cijepljenih P/LAIV A/Vietnam/1203/2004 cjepivom također je nadišao onaj zamijećen nakon 2 doze inaktiviranog cjepiva u ispitanika koji nisu bili izloženi P/LAIV cjepivu (vidjeti tablicu 3).
The antibody response to other vaccines may be diminished (see also 4.4).
Odgovor antitijela na druga cjepiva mogao bi biti slabiji (vidjeti i dio 4.4).
The anticholinergic activity of oxybutynin is increased by concurrent use of other anticholinergics or medicinal products with anticholinergic activity, such as amantadine and other anticholinergic antiparkinsonian medicinal products (e.g. biperiden, levodopa), antihistamines, antipsychotics (e.g. phenothiazines, butyrophenones, clozapine), quinidine, tricyclic antidepressants, atropine and related compounds like atropinic antispasmodics, and dipyridamole.
Antikolinergička aktivnost oksibutinina povećava se istodobnom primjenom drugih antikolinergika ili lijekova s antikolinergičkom aktivnošću, poput amantadina i drugih antikolinergičkih antiparkinsonika (npr. biperiden, levodopa), antihistaminika, antipsihotika (npr. fenotiazina, butirofenona, klozapina), kinidina, tricikličkih antidepresiva, atropina i povezanih spojeva, poput atropinskih spazmolitika te dipiridamola.
The anticholinergic activity of oxybutynin is increased by concurrent use of other anticholinergics or medicinal products with anticholinergic activity, such as amantadine and other anticholinergic antiparkinsonian medicinal products (e.g. biperiden, levodopa), antihistamines, antipsychotics (e.g. phenothiazines, butyrophenones, clozapine), quinidine, tricyclic antidepressants, atropine and related compounds like atropinic antispasmodics, dipyridamole.
Antikolinergička aktivnost oksibutinina povećava se istodobnom primjenom drugih antikolinergika ili lijekova s antikolinergičkom aktivnošću, poput amantadina i drugih antikolinergičkih antiparkinsonika (npr. biperiden, levodopa), antihistaminika, antipsihotika (npr. fenotiazina, butirofenona, klozapina), kinidina, tricikličkih antidepresiva, atropina i povezanih spojeva, poput atropinskih spazmolitika te dipiridamola.
The anticipated clinical benefit resulting from a combination of dinotefuran with permethrin was demonstrated in one laboratory study on dogs which showed a prolongation of the duration of efficacy against C. canis fleas to 4 weeks.
Očekivana klinička korist kombinacije dinotefurana i permetrina dokazana je u jednom laboratorijskom ispitivanju na psima koje je pokazalo produljenje djelotvornosti protiv buha C. canis na 4 tjedna.
The anticoagulant effects can be largely neutralised by the slow intravenous injection of protamine sulphate or protamine hydrochloride.
Antikoagulacijski učinak može se u velikoj mjeri neutralizirati sporom intravenskom injekcijom protamin-sulfata ili protaminklorida.
The anticoagulant effects can be largely neutralised by the slow intravenous injection of protamine sulphate or protamine hydrochloride.
Antikoagulacijski učinak može se u velikoj mjeri neutralizirati sporom intravenskom injekcijom protaminsulfata ili protaminklorida.
The anticonvulsant activity of zonisamide has been evaluated in a variety of models, in several species with induced or innate seizures, and zonisamide appears to act as a broad-spectrum anti-epileptic in these models.
Antikonvulzivno djelovanje zonisamida procijenjeno je na različitim modelima u više životinjskih vrsta s induciranim ili prirodnim napadajima, i čini se da zonisamid u tim modelima djeluje kao antiepileptik širokog spektra.
the anticonvulsants carbamazepine, oxcarbazepine, phenobarbital, phenytoin
antikonvulzivi karbamazepin, okskarbazepin, fenobarbital, fenitoin
the anticonvulsants carbamazepine, oxcarbazepine, phenobarbital, phenytoin;
antikonvulzivi karbamazepin, okskarbazepin, fenobarbital, fenitoin;
The antiemetic agent, domperidone, has the potential to increase QT interval prolongation and to induce “torsade de pointes”- arrhythmias; therefore, co-administration with domperidone should be avoided.
Antiemetik domperidon ima potencijal produljiti QT interval i izazvati aritimije "torsade de pointes", stoga je nužno izbjeći istodobnu primjenu domperidona.
The antiepileptic drug hypersensitivity syndrome occurred in close temporal association to the initiation of rufinamide therapy and in the paediatric population.
Nastanak sindroma preosjetljivosti na antiepileptičke lijekove usko je vremenski povezan s početkom terapije rufinamidom te s pedijatrijskom populacijom.
The antifungal treatment should continue for at least one week after two sequential negative blood cultures have been obtained and after resolution of clinical signs and symptoms of infection.
Antifungalno liječenje treba nastaviti najmanje tjedan dana nakon što se uzastopno dobiju dvije negativne hemokulture i nakon nestanka kliničkih znakova i simptoma infekcije.
The antifungal treatment should continue for at least one week after two sequential negative blood cultures have been obtained and after resolution of clinical signs and symptoms of infection.
Antifungalno liječenje treba se nastaviti još najmanje jedan tjedan nakon što se uzastopno dobiju dvije negativne hemokulture i nakon nestanka kliničkih znakova i simptoma infekcije.
The antigen is expressed on 95 % of all B cell non-Hodgkin’s lymphomas.
Antigen je izražen u > 95% svih B-staničnih ne-Hodgkinovih limfoma.
The antigen to which nivolumab has been designed to attach is a receptor called ‘programmed cell death-1’ (PD-1), which switches off the activity of certain cells of the immune system (the body’s natural defences) called T cells.
Protutjelo za koji je novolumab dizajniran da se vezuje je receptor naziva "programirana stanična smrt-1" (PD-1), koji isključuje djelovanje određenih stanica imunosnog sustava (prirodne obrane tijela) naziva T stanice.
The antigens are adjuvanted with 150 mg dl--tocopherol acetate per dose.
Jedna doza antigena, sadrži 150 mg dl-α- tokaferola acetat kao adjuvans.
The antihypertensive effect is substantially present within two weeks (85-90%) after initiating therapy with 150 mg once daily.
Antihipertenzivni učinak je značajno prisutan unutar dva tjedna (85-90%) nakon početka terapije sa 150 mg jednput dnevno.
The antihypertensive effect persists constantly over 24 hours after dosing and includes the last 4 hours before the next dose as shown by ambulatory blood pressure measurements.
Anihipertenzivni učinak zadržava se neprekidno tijekom 24 sata nakon doziranja te uključuje posljednja 4 sata prije sljedeće doze, kao što je pokazano ambulantnim mjerenjima krvnog tlaka.
The antimicrobial effectiveness of valnemulin against bacteria causing the claimed diseases in pigs was studied in microbiological laboratories.
Antimikrobna aktivnost valnemulina protiv bakterija koje uzrokuju navedene bolesti u svinja ispitana je u mikrobiološkim laboratorijima.
the antimycobacterials rifampicin, rifapentine
antimikobakterijski lijekovi rifampicin, rifapentin
the antimycobacterials rifampicin, rifapentine;
antimikobakterici rifampicin, rifapentin;
The antithrombotic activity is mediated by antithrombin III (ATIII), resulting in human antithrombotic effect.
Antitrombotička aktivnost posredovana je antitrombinom III (ATIII), što kod ljudi rezultira antitrombotičkim učinkom.
The antithrombotic activity of fondaparinux is the result of antithrombin III (ATIII) mediated selective inhibition of Factor Xa.
Antitrombotsko djelovanje fondaparinuksa rezultat je selektivne inhibicije faktora Xa preko antitrombina III (AT III).
The antitumour efficacy of crizotinib was dose-dependent and correlated to pharmacodynamic inhibition of phosphorylation of ALK fusion proteins (including EML4-ALK and NPM-ALK) in tumours in vivo.
Antitumorska djelotvornost krizotiniba bila je ovisna o dozi i odgovarala je farmakodinamičkoj inhibiciji fosforilacije proteina ALK-inačica nastalih fuzijom (isključujući EML4- ALK i NPM-ALK) u tumorima in vivo.
The antiviral activity of elvitegravir against laboratory and clinical isolates of HIV-1 was assessed in lymphoblastoid cells, monocyte/macrophage cells, and peripheral blood lymphocytes and the 50% effective concentration (EC50) values were in the range of 0.02 to 1.7 nM.
Antivirusna aktivnost elvitegravira na laboratorijske i kliničke izolate HIV-1 procijenjena je na limfoblastoidnim stanicama, monocitnim/makrofagnim stanicama i limfocitima periferne krvi, te su vrijednosti 50%-tne djelotvorne koncentracije (EC50) bile u rasponu od 0,02 do 1,7 nM.
The antiviral activity of elvitegravir against laboratory and clinical isolates of HIV-1 was assessed in lymphoblastoid cells, monocyte/macrophage cells, and peripheral blood lymphocytes and the 50% effective concentration (EC50) values were in the range of 0.02 to 1.7 nM.
Antivirusno djelovanje elvitegravira na laboratorijske i kliničke izolate virusa HIV-1 procijenjeno je na limfoblastoidnim stanicama, monocitnim/makrofagnim stanicama i limfocitima periferne krvi, te su vrijednosti 50%-tne djelotvorne koncentracije (EC50) bile u rasponu od 0,02 do 1,7 nM.
The antiviral activity of elvitegravir against laboratory and clinical isolates of HIV-1 was assessed in lymphoblastoid cells, monocyte/macrophage cells, and peripheral blood lymphocytes and the 50% effective concentration (EC50) values were in the range of 0.02 to 1.7 nM.
Antivirusno djelovanje elvitegravira na laboratorijske i kliničke izolate virusa HIV-1 procijenjeno je na limfoblastoidnim stanicama, monocitnim/makrofagnim stanicama i limfocitima periferne krvi, te su vrijednosti 50%-tne učinkovite koncentracije (EC50) bile u rasponu od 0,02 do 1,7 nM.
The antiviral activity of tenofovir alafenamide against laboratory and clinical isolates of HIV-1 subtype B was assessed in lymphoblastoid cell lines, PBMCs, primary monocyte/macrophage cells, and CD4+-T lymphocytes.
Antivirusna aktivnost tenofoviralafenamida na laboratorijske i kliničke izolate virusa HIV-1 podtipa B procijenjena je na limfoblastoidnim staničnim linijama, PBMC-ovima, primarnim monocitnim/makrofagnim stanicama i CD4+-T limfocitima.
The antiviral activity of tenofovir disoproxil fumarate against hepatitis B virus (HBV) has been demonstrated in vitro and clinically in adults and adolescents.
Antivirusna aktivnost tenofovirdizoproksilfumarata protiv virusa hepatitisa B (HBV) dokazana je in vitro i klinički u odraslih i adolescenata.
The antiviral response to tenofovir disoproxil fumarate was durable through 48 weeks (DAVG48 was -0.57 log10 copies/ml, proportion of patients with HIV-1 RNA below 400 or 50 copies/ml was 41% and 18% respectively).
Antivirusni odgovor na tenofovirdizoproksilfumarat trajao je 48 tjedana (DAVG48 bila je -0,57 log10 kopija/ml, udio pacijenata s HIV-1 RNK ispod 400 ili 50 kopija/ml bio je 41%, odnosno 18%).
The APEX Study evaluated efficacy in 40 patients with renal impairment (i.e., baseline serum creatinine > 1.5 mg/dL and 2.0 mg/dL).
U ispitivanju APEX procjenjivana je djelotvornost kod 40 bolesnika s oštećenom funkcijom bubrega (tj. početna razina kreatinina u serumu >1,5 mg/dl i ≤2,0 mg/dl).
The APEX study showed statistically significant superiority of both the ADENURIC 80 mg QD and the ADENURIC 120 mg QD treatment arms versus the conventionally used doses of allopurinol 300 mg (n = 258) /100 mg (n = 10) treatment arm in reducing the sUA below 6 mg/dL (357 µmol/L) (see Table 2 and Figure 1).
Ispitivanje APEX pokazalo je statistički značajnu superiornost liječenja, kako ADENURICOM 80 mg jednom dnevno tako i ADENURICOM 120 mg jednom dnevno u odnosu na liječenje uobičajeno korištenim dozama alopurinola 300 mg (n = 258)/100mg (n = 10), s obzirom na snižavanje razine mokraćne kiseline u serumu ispod 6 mg/dl (357 µmol/l) (vidjeti tablicu 2 i sliku 1).
The Apidra cartridges are to be used only in conjunction with the pens: OptiPen, ClikSTAR, Autopen 24, Tactipen, AllStar or JuniorSTAR (see section 4.4).
Apidra ulošci smiju se upotrebljavati samo s brizgalicama: OptiPen, ClikSTAR, Autopen 24, Tactipen, AllStar ili JuniorSTAR (vidjeti dio 4.4).
The Apidra cartridges are to be used only with the pens: OptiPen, ClikSTAR, Tactipen, Autopen 24, AllStar, JuniorSTAR.
Apidra ulošci smiju se koristiti samo u kombinaciji s brizgalicama: OptiPen, ClikSTAR, Tactipen, Autopen 24, AllStar, JuniorSTAR.
The Apidra cartridges should only be used with the following pens:
Apidra ulošci smiju se upotrebljavati samo sa sljedećim brizgalicama:
The apixaban clinical program was designed to demonstrate the efficacy and safety of apixaban for the prevention of VTE in a broad range of adult patients undergoing elective hip or knee replacement.
Klinički program za apiksaban osmišljen je kako bi pokazao djelotvornost i sigurnost apiksabana u prevenciji venskih tromboembolijskih događaja u širokom rasponu odraslih bolesnika koji su podvrgnuti elektivnom zahvatu ugradnje endoproteze kuka ili koljena.
The apparent clearance of ara-G (Cl/F) is comparable between the two groups [9.5 l/h/m2 (35 %) in adult patients and 10.8 l/h/m2 (36 %) in paediatric patients] on day 1.
Klirens ara-G (Cl/F), zabilježen 1. dana liječenja usporediv je u obje ispitivane skupine [9,5 l/h/m2 (35%) u odraslih bolesnika, odnosno 10,8 l/h/m2 (36%) u pedijatrijskih bolesnika].
the apparent clearance of nevirapine
povećanje vidljivog klirensa nevirapina
The apparent distribution volume of telavancin at steady-state in healthy adult subjects was approximately 133 ml/kg.
Prividni volumen distribucije telavancina u stanju dinamičke ravnoteže za zdravu odraslu osobu bila je približno 133 ml/kg.
The apparent effects were greater during chronic than acute administration.
Vidljivi učinci su bili veći pri kroničnoj nego akutnoj primjeni.
The apparent elimination half-life is 4.5 hours whereas the radioactive half-life of flutemetamol (18F) is 110 minutes.
Prividni poluvijek eliminacije iznosi 4,5 sata dok radioaktivni poluvijek flutemetamola (18F) iznosi 110 minuta.
The apparent half-life following topical dosing of 3.75% imiquimod cream in the pharmacokinetic study was calculated as approximately 29 hours.
Izračunati prividni poluvijek nakon topikalnog doziranja imikvimod 3,75 % kreme u farmakokinetičkom ispitivanju bio je približno 29 sati.
The apparent half-life ranged from 24-231 hours, with a mean of 73.9 hours.
Prividni poluvijek kretao se u rasponu 24 – 231 sat, uz prosjek od 73,9 sati.
The apparent molecular weight of erythropoietin is 32 000-40 000 Dalton.
Prividna molekularna težina eritropoetina je 32 000 – 40 000 Daltona.
The apparent oral volume of distribution at steady state of tasimelteon in young healthy subjects is approximately 59 - 126 L. At therapeutic concentrations, tasimelteon is about 88.6 – 90.1% bound to proteins.
Prividni volumen distribucije tazimelteona u stanju dinamičke ravnoteže nakon peroralne primjene u mladih zdravih ispitanika iznosi otprilike 59 – 126 L. Pri terapijskim koncentracijama, tazimelteon se veže za bjelančevine otprilike 88,6 – 90,1 %.
The apparent terminal half-life of tobramycin in serum after inhalation of a 112 mg single dose of TOBI Podhaler was approximately 3 hours in cystic fibrosis patients and consistent with the half-life of tobramycin after inhalation of tobramycin 300 mg/5 ml nebuliser solution (TOBI).
Prividni terminalni poluvijek tobramicina u serumu nakon inhalacije jednokratne doze od 112 mg TOBI Podhalera bio je otprilike 3 sata u bolesnika s cističnom fibrozom i u skladu s poluvijekom tobramicina nakon inhalacije tobramicin 300 mg/5 ml otopine za nebulizator (TOBI).
The apparent total body clearance at steady state (CL/F) increased with age over the 3-month period with a corresponding decrease in AUC.
Prividni klirens iz cijelog tijela u stanju dinamičke ravnoteže (CL/F) povećavao se s dobi tijekom tromjesečnog razdoblja uz odgovarajuće smanjenje AUC-a.
The apparent volume of distribution (V/F) was estimated at 8.01 l in a population pharmacokinetic analysis of patients with rheumatoid arthritis.
Populacijskom farmakokinetičkom analizom prividan volumen distribucije (V/F) u bolesnika s reumatoidnim artritisom procijenjen je na 8,01 l.
The apparent volume of distribution (Vd) for sunitinib was large, 2230 l, indicating distribution into the tissues.
Prividni volumen raspodjele (Vd) sunitiniba je bio velik, 2 230 l, što ukazuje da se raspodjeljuje u tkiva.
The apparent volume of distribution (Vd) is 2.2 l/kg and the elimination half-life t1⁄2) is one hour.
Prividni volumen raspodjele (Vd) iznosi 2,2 l/kg, a poluvrijeme eliminacije (t½) jedan sat.
The apparent volume of distribution after intravenous administration of emtricitabine was 1.4±0.3 l/kg, indicating that emtricitabine is widely distributed throughout the body to both intracellular and extracellular fluid spaces.
Prividni volumen distribucije nakon intravenske primjene emtricitabina bio je 1,4±0,3 l/kg, što upućuje na to da se emtricitabin široko raspodjeljuje po tijelu u prostore unutarstaničnih i izvanstaničnih tekućina.
The apparent volume of distribution after subcutaneous administration is 11­17 l.
Prividan volumen distribucije nakon supkutane primjene je 11-17 l.
The apparent volume of distribution at steady state is 46±21 l.
Prividni volumen distribucije u stanju dinamičke ravnoteže je 46±21 l.
The apparent volume of distribution is 17 L to 20 L in HIV-infected patients, based on a population pharmacokinetic analysis.
Na temelju populacijske farmakokinetičke analize, prividni volumen distribucije u bolesnika s HIV infekcijom kreće se u rasponu od 17 l do 20 l.
The apparent volume of distribution is 487 l.
Prividni volumen raspodjele je 487 l.
The apparent volume of distribution is about 1.1 – 1.7 l/kg in adults indicating that zonisamide is extensively distributed to tissues.
Prividni volumen distribucije iznosi oko 1,1 - 1,7 l/kg u odraslih što pokazuje da se zonisamid opsežno raspodjeljuje u tkiva.
The apparent volume of distribution of amprenavir following administration of Telzir is approximately 430 l (6 l/kg assuming a 70 kg body weight), suggesting a large volume of distribution, with penetration of amprenavir freely into tissues beyond the systemic circulation.
Očiti volumen distribucije amprenavira nakon primjene lijeka Telzir je oko 430 l (6 l/kg uz pretpostavku tjelesne težine od 70 kg) što upućuje na velik volumen distribucije sa slobodnim prodiranjem amprenavira u tkiva izvan sistemske cirkulacije.
The apparent volume of distribution of miglustat is 83 l.
Prividni volumen distribucije miglustata je 83 l.
The apparent volume of distribution of nomegestrol acetate at steady-state is 1,645  576 l.
Prividan volumen distribucije nomegestrolacetata u stanju dinamičke ravnoteže iznosi 1,645  576 l.
The apparent volume of distribution of pegvisomant is relatively small (7-12 L).
Prividni volumen distribucije pegvisomanta relativno je malen (7-12 l ).
The appearance of insulin should also be checked: the insulin solution must be clear, colourless, with no solid particles visible, and must have a water-like consistency.
Treba provjeriti i izgled inzulina: otopina inzulina mora biti bistra, bezbojna, vodenasta i bez vidljivih krutih čestica.
The appearance of insulin should also be checked: the insulin solution must be clear, colourless, with no solid particles visible, and must have a water-like consistency.
Treba provjeriti i izgled inzulina: otopina inzulina mora biti bistra, bezbojna, vodenaste konzistencije i bez vidljivih krutih čestica.
The appearance of the insulin should be checked: the insulin suspension must have an evenly milky-white appearance.
Treba provjeriti i izgled inzulina: suspenzija inzulina mora biti jednoliko mliječna.
The appearance of the reconstituted solution is the same as the appearance of the diluent.
Pripremljena otopina izgledom mora biti jednaka otapalu.
The Applicant has committed to provide data from an on-going COG study AALL0434.
Nositelj odobrenja se obvezao predočiti podatke iz COG ispitivanja AALL0434 koje je u tijeku.